Hepatocellular carcinoma in patients with acute hepatic porphyria: Frequency of occurrence and related factors

Journal of Hepatology

Volumn 32, Issue 6, 2000, Pages 933-939

  Andant, Christophe ^c   Puy, Hervé ^a   Bogard, Catherine ^a   Faivre, Jean ^a   Soulé, Jean Claude ^c   Nordmann, Yves ^a   Deybach, Jean Charles ^a,b  

^a INSERM   (France)

^b Jean Charles Deybach   (France)

^c Hop Louis M ^*

Author keywords

Acute intermittent porphyria; Hepatocellular carcinoma; Hereditary coproporphyria; Variegate porphyria; aminolevulinic acid

Indexed keywords

AMINOLEVULINIC ACID;

ADULT; ARTICLE; BIOSYNTHESIS; CANCER RISK; CARCINOGENESIS; DISEASE ASSOCIATION; FEMALE; HEPATIC PORPHYRIA; HUMAN; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PORPHYRIA VARIEGATA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TUMOR SUPPRESSOR GENE;

EID: 0034098286     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(00)80097-5     Document Type: Article

References (43)

1. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. Scriver CR, Beaudet AL, Sly WS, Valle D. The Metabolic Basis of Inherited Disease, Vol. 2, 7th ed. 1995;2103-2159 McGraw-Hill, New York.
2. Puy H, Deybach JC, Lamoril J, Robreau AM, Da Silva V, Gouya L, et al. Molecular epidemiology and diagnosis of PBG deaminase gene defect in acute intermittent porphyria. Am J Hum Genet. 60:1997;1373-1383.
3. Nordmann Y, Puy H, Da Silva V, Simonin S, Robreau AM, Bonaiti C, et al. Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France. J Int Med. 242:1997;213-217.
4. Boutron MC, Faivre J, Milan C, Bedenne L, Hillon P, Klepping C. Primary liver cancer in Cote d'Or. (France) Int J Epidemiol. 17:1988;21-26.
5. Hardell L, Bengtsson NO, Jonsson U, Eriksson S, Larsson LG. Aetiological aspects on primary liver cancer with special regard to alcohol, organic solvents and acute intermittent porphyria, an epidemiological investigation. Br J Cancer. 50:1984;389-397.
6. Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi S, et al. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proc Natl Acad Sci USA. 87:1990;6547-6549.
7. Johnson PJ, Krasner N, Portmann B, Eddleston AL, Williams R. Hepatocellular carcinoma in Great Britain: influence of age, sex, HBsAg status, and aetiology of underlying cirrhosis. Gut. 19:1978;1022-1026.
8. Lithner F, Wetterberg L. Hepatocellular carcinoma in patients with acute intermittent porphyria. Acta Med Scand. 215:1984;271-274.
9. Tidman J, Higgins EM, Elder GH, Mac Donald DM. Variegate porphyria associated with hepatocellular carcinoma. Br J Dermatol. 121:1989;503-505.
10. Germanaud J, Luthier F, Causse X, Kerdraon R, Grossetti D, Gargot D, et al. A case of association between hepatocellular carcinoma and porphyria variegata. Scand J Gastroenterol. 29:1994;671-672.
11. Gubler JG, Bargetzi MJ, Meyer UA. Primary liver carcinoma in two sisters with acute intermittent porphyria. Am J Med. 89:1990;540-541.
12. Andant C, Puy H, Deybach JC, Soulé JC, Nordmann Y. Concomitant hepatocellular carcinoma in a case of hereditary coproporphyria. Am J Gastroenterol. 92:1997;1389-1390.
13. Kauppinen R, Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer. 57:1988;117-120.
14. Andersson C, Bjersing L, Lithner F. The epidemiology of hepatocellular carcinoma in patients with acute intermittent porphyria. J Intern Med. 240:1996;195-201.
15. Oteiza PI, Kleinmamn CG, Demasi M, Bechara EJ. δ aminolevulinic acid induces iron release from ferritin. Arch Biochem Biophys. 316:1995;607-611.
16. Carneiro RG, Reiter RJ. Melatonin protects against lipid peroxidation induced by δ aminolevulinic acid in rat cerebellum, cortex and hippocampus. Neuroscience. 82:1998;293-299.
17. Brzezinski A. Melatonin in humans. N Engl J Med. 336:1997;186-195.
18. Puy H, Deybach JC, Baudry P, Callebert J, Touitou Y, Nordmann Y. Decreased nocturnal plasma melatonin levels in patients with recurrent acute intermittent porphyria attacks. Life Sci. 53:1993;621-627.
19. Puy H, Deybach JC, Bogdan A, Callebert J, Baumgartner M, Voisin P, et al. Increased δ aminolevulinic acid and decreased pineal melatonin production: a common event in acute intermittent porphyria. Studies in the rat. J Clin Invest. 97:1996;1-7.
20. French Study Group for the Standardization of Hepatitis C Virus PCR: improvement of hepatitis C virus RNA polymerase chain reaction through a multicentre quality control study. J Virol Methods. 49:1994;79-88.
21. Mauzerall D, Granick SJ. The occurrence and determination of aminolevulinic acid and porphobilinogen in urine. J Biol Chem. 219:1956;435-446.
22. Rosipal R, Lamoril J, Puy H, Da Silva V, Gouya L, De Rooij FWM, et al. Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update. Hum Mut. 13:1999;44-53.
23. Roberts A, Puy H, Dailey TA, Morgan RR, Whatley SD, Dailey HA, et al. Molecular characterization of homozygous variegate porphyria. Hum Mol Genet. 7:1998;1921-1925.
24. Faivre J, Grosclaude P, Launoy G, Arveux P, Raverdy N, Menegoz F, et al. Digestive cancers in France. Geographic distribution and estimation of national incidence. Gastroenterol Clin Biol. 21:1997;174-180.
25. Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med. 108:1988;390-401.
26. Jensen OM, Esteve J, Moller M, Renard H. Cancer in the European Community and its member states. Eur J Cancer. 26:1990;1167-1256.
27. Andant C, Puy H, Faivre J, Deybach JC. Acute hepatic porphyrias and primary liver cancer. [letter] N Engl J Med. 338:1998;1853-1854.
28. Salata H, Cortes JM, Enriquez de Salamanca R, Oliva H, Castro A, Kusak E, et al. Porphyria cutanea tarda and hepatocellular carcinoma. Frequency of occurrence and related factors. J Hepatol. 1:1985;477-487.
29. Lamoril J, Andant C, Bogard C, Puy H, Gouya L, Pawlotsky JM, et al. Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda. Hepatology. 27:1998;848-852.
30. Bjersing L, Andersson C, Lithner F. Hepatocellular carcinoma in patients from Northern Sweden with acute intermittent porphyria: morphology and mutations. Cancer Epidemiol. Biomarkers Prev. 5:1996;393-397.
31. Heilmann E, Muller KM, Niedorf H, Bassewitz DB. Special clinical, light and electron microscopic aspects of acute intermittent porphyria. Ann Clin Res. 8:1976;213-216.
32. Doss M, Martini GA. Porphyrin metabolism and liver tumors. Remmer H, Bolt HM, Bannasch P, Popper H. Primary Liver Tumors. 1978;409-420 University Park Press, Baltimore.
33. Hermes-Lima M, Valle VG, Vercesi AK, Bechara EJ. Damage to rat liver mitochondria promoted by δ aminolevulinic acid-generated reactive oxygen species: connections with acute intermittent porphyria and lead poisoning. Biochim Biophys Acta. 1056:1991;57-63.
34. Monteiro HP, Bechara EJ, Abdalla DS. Free radicals involvement in neurological porphyrias and lead poisoning. Mol Cell Biochem. 103:1991;73-83.
35. 2+ ions. Biochim Biophys Acta. 1225:1994;259-263.
36. Sun Y. Free radicals, antioxidant enzymes and carcinogenesis. Free Radic Biol Med. 8:1990;583-599.
37. Carneiro RC, Reiter RJ. δ aminolevulinic acid-induced lipid peroxidation in rat kidney and liver is attenuated by melatonin: an in vitro and in vivo study. J Pineal Res. 24:1998;131-136.
38. Battle AM. Porphyrins, porphyrias, cancer and photodynamic therapy - a model for carcinogenesis. J Photochem Photobiol B. 20:1993;5-22.
39. Sesto ME, Vogt DP, Hermann RE. Hepatic resection in 128 patients: a 24-year experience. Surgery. 102:1987;846-851.
40. Stuart KE, Anand AJ, Jenkins RL. Hepatocellular carcinoma in the United States. Prognostic features, treatment outcome, and survival. Cancer. 77:1996;2217-2222.
41. Lise M, Bacchetti S, da Pian P, Nitti D, Pilati PL, Pigato P. Prognostic factors affecting long term outcome after liver resection for hepatocellular carcinoma: results in a series of 100 Italian patients. Cancer. 82:1998;1028-1036.
42. The Liver Cancer Study Group of Japan. Predictive factors for long term prognosis after partial hepatectomy for patients with hepatocellular carcinoma in Japan. Cancer. 74:1994;2772-2780.
43. Izumi R, Shimizu K, Ii T, Yagi lM, Matsui O, Nononura A, et al. Prognostic factors of hepatocellular carcinoma in patients undergoing hepatic resection. Gastroenterology. 106:1994;720-727.